Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Dave Dalry who wrote (225)	3/19/1998 4:27:00 PM
From: CHIPNHOLE	Respond to of 2887

Dave This is a an opportunity to buy more, And that is what I will be doing in the morning. I do not think that there will be to many more opportunities. Goodl luck to everyone in there trading

To: Dave Dalry who wrote (225)	3/19/1998 10:05:00 PM
From: Jeffrey L. Henken	Read Replies (5) \| Respond to of 2887

Fear and Greed! As investors we are ruled by these emotions. We all happily have bought into a rising stock feeling like that rise will never end. After all, all those other investors must know something! It's obvious that they do because no one could be selling when a stock rises so rapidly. Ha! That's greed talking. What about fear? On days like today when a stock you own drops what feels like a tremendous amount it's easy to panic and feel like joining the sellers. You might think I had better sell before I have nothing left to sell! The company is running out of cash! The stock is too risky! If they had any good products then they would already be profitable! If anyone was going to buy them out they would already be bought! Ha! That's fear talking. Now lets talk rationally shall we? American BioMed has made a tremendous amount of progress in the last few months towards regaining some shareholder value. The share price has risen from a low of .23 cents not that long ago to trade at 66 cents on Monday. All with virtually no news until yesterday. Did the stock sell off because the notification of the receipt of an OmniCath patent was found to be less than exciting? Did the stock sell off because people were expecting better news? Did the stock sell off simply because fear got the better of a lot of people? Does it even matter? No not really because if you are in this stock long term then you are looking for more a lot than 52 cents as an exit point. I personally think the stock is going much higher and I'll tell you why: First off American BioMed has the only 100% silicone catheter line up in the business. Latex allergies are very real. A recent million dollar judgement against a company who makes latex gloves increases the probability that lawsuits dealing with latex allergies will become more prevalent. execpc.com Especially if a surgical patient dies from anaphylatic shock. This unfortunately is bound to happen sooner or later. American BioMed is the only company who offers a 100% silicone catheter line up to help prevent these severe allergic reactions. latex.org americanbiomed.com I have talked to both CEO Steve Rash and Dr. Samuel Ahn the company's Chief Clinical Advisor recently and I am more convinced that ever that these catheters have an excellent chance of becoming mainstream products. I specifically asked Dr Ahn how well these catheters will be accepted in the hands of physicians accustomed to other products. I have to tell you Dr Ahn is no great salesman, just an honest physician who spoke with me with total candor. Despite the fact that we all resist change sometimes change is for the better. Such is the case with American BioMed's 100% silicone catheters. So while it will be difficult to expect overnight acceptance of silicone catheters it will happen because physicians will like them more than current latex products. They have other advantages besides the all silicone design. Eventually hospital administrators and physician's will clamor towards products like these that will reduce the opportunity of a malpractice suit. americanbiomed.com I expect FDA approval of more of the company's catheter product line soon. Don't forget the recent approval of the Ahn Thrombectomy Catheter. americanbiomed.com American BioMed's distribution network should be rounded out soon to cover all of North America and Europe. Distributors such as Stepic in New York only sign to distribute a company's products if they believe they can move at least $2 million worth of those products in a given year. American BioMed is paid up front for the products they ship to the distributors. Expect the announcement of further distribution agreements soon. biz.yahoo.com americanbiomed.com americanbiomed.com americanbiomed.com How about ABMI's recent ISO 9001 approval? What does this mean to the company and it's shareholders? Money! Dough! Cash! Payola! High profit margins without any added R&D or marketing to detract from the financial gains. Very few companies have ISO 9001 certification. CE Mark approval will be coming soon as well. This means big business for American BioMed and it already brought us the Polamedco deal. In the weeks ahead I believe we will see further OEM deals announced. Deals like these add immensely to the bottom line and help to fund further research: biz.yahoo.com How about the other products that American BioMed is researching? While they still remain many months to years away from FDA approval their value cannot be discounted on that basis alone. Products like the OmniCath which received an additional patent yesterday have significant advantages over some of the competitors products. What are some of those advantages? The OmniCath safely removes atherosclerotic plaque shaving it away near the end of the device and then uses suction to remove it. This allows Physicians to take care of even multiple lesions with only one placement. There is no blockage of blood flow as with a more traditional placement of a balloon catheter. This allows the physician all the time necessary to complete a procedure although generally less time is actually needed: americanbiomed.com Don't think I've researched those other products? See some of them for yourself: guidant.com bsci.com bsci.com Some disgruntled shareholders will tell you that despite innovative products like the OmniCath the company has no technology that would be exciting to the bigger players in this industry. That's a crock! American BioMed now has 27 patents, some excellent technology in R&D and the 100% silicone catheter line up. The company is more ripe for a buy out than at any other time in the company's history. So who might be interested? How about Baxter International the company that invented the catheter? baxter.com How about Johnson & Johnson a company that has been very active buying small companies in the past: devicelink.com Or Guidant the company that has recently dominated the stent market. Would they find American BioMed's OmniStents a nice addition to their products? I bet they would: biz.yahoo.com americanbiomed.com How about Medtronic? They bought Instent for $200 million: medtronic.com There are other companies as well that could find ABMI's minuscule market cap so easy to swallow for just the extra patent protection alone. But what if there is never any buy out? Can American BioMed survive without massive infusions of cash? Will there be another private placement causing eventual earnings dilution? It's going to happen. Sorry but lets face facts, American BioMed is turning the corner towards profitability but they still need cash. There will be a private placement but it will not be some underhanded Reg S done overseas and sneaked past investors hopelessly inflating the number of shares beyond investor's greatest fears. Yes the new shares will be issued below market cost to large investors. But those new investor's will be married to the stock for a significantly long period of time. In other words even though they might get their shares for less than we could buy it on the open market they won't be able to sell for a long time. So why would they buy the shares besides the lower cost if they have to hold their shares so long? Because they believe like I do that American BioMed is a tremendous little company well on it's way to profitability in 1999. At the end of this month I expect we will see an earnings report released that will show a real rise in revenues. Some day increasing revenues will mean actual earnings hopefully rapidly growing earnings. In the weeks and months ahead look for announcements from the company that will show real progress towards profitability. Regards, Jeff